Secondary Stock Offerings
By The Online Investor Staff, updated Sun., Apr. 11, 8:00 PM
| This Slide: #3 of 25 |
Slide #3. Crinetics Pharmaceuticals, Inc. — Secondary Offering
Company:
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Date announced:
4/7/2021
Shares Offered:
4,562,044
Date of Pricing:
4/7/2021
Price Per Share:
$16.44
Secondary Offering Details:
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing conditions.
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. CRN00808, Co.'s main product candidate, establishes a class of oral selective nonpeptide somatostatin receptor type 2 (sst2) biased agonists designed for the treatment of acromegaly. CRN0194 is an oral nonpeptide sst2 biased agonist for the treatment of neuroendocrine tumors that originate from neuroendocrine cells commonly found in the gut, lung or pancreas. Co. develops a class of oral selective nonpeptide somatostatin type 5 receptor agonists designed to treat congenital hyperinsulinism.
CRNX SEC Filing Email Alerts Service
Open the CRNX Page at The Online Investor »
|
|||||||||||||||||||||
Open the CRNX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.60 out of 4) 63rd percentile
(ranked higher than approx. 63% of all stocks covered)
Analysts' Target Price: CRNX Stock Forecast Based on Zacks ABR data; powered by Xignite |
